<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="43392">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01711125</url>
  </required_header>
  <id_info>
    <org_study_id>X11-0154</org_study_id>
    <nct_id>NCT01711125</nct_id>
  </id_info>
  <brief_title>Baclofen in the Treatment of Alcoholic Liver Disease</brief_title>
  <official_title>Exploring the Efficacy and Biobehavioural Basis of Baclofen in the Treatment of Alcoholic Liver Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>South West Sydney Local Health District</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Health and Medical Research Council, Australia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Sydney</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>South West Sydney Local Health District</source>
  <oversight_info>
    <authority>Australia: Department of Health and Ageing Therapeutic Goods Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To explore the effectiveness and biobehavioural basis of baclofen in improving treatment
      outcomes for alcohol dependence in people with alcoholic cirrhosis in a double-blind
      randomised placebo-controlled trial.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a double-blind randomised placebo-controlled study investigating the efficacy of
      baclofen for the treatment of alcohol dependence in patients with alcoholic liver disease.
      Medications will be given for 12 weeks, with a further 6 months follow-up. Both male and
      female participants will be recruited to this study. Trial patients will be randomised to
      one of three treatment groups: (1) baclofen 30mg/day (10 mg t.i.d), (2) baclofen 75mg/day
      (25 mg t.i.d) or (3) Placebo (3 matched tabs/day).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Anticipated">March 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>alcohol consumption</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>as measured by the number of days abstinent, number of heavy drinking days, time to relapse, time to lapse and number of drinks per drinking day</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>clinical markers of liver injury</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence of hepatic side effects</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>craving for alcohol</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>early termination due to side effects</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Alcoholic Liver Disease</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Baclofen low dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Baclofen high dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Baclofen 30mg/day</intervention_name>
    <description>30mg/day 10 mg t.i.d</description>
    <arm_group_label>Arm 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Baclofen 75mg/day</intervention_name>
    <description>75mg/day 25 mg t.i.d</description>
    <arm_group_label>Arm 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo 3 matched tabs/day</description>
    <arm_group_label>Arm 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ALD, defined as the presence of symptoms and/or signs referable to liver disease with
             or without cirrhosis, in which alcohol use is considered to play a major aetiological
             role. Alcohol use will have exceeded an average of 60g/day in women and 80g/day in
             men for &gt;10 years.

          -  Alcohol dependence according to the ICD-10 criteria

          -  Adequate cognition and English language skills to give valid consent and complete
             research interviews

          -  Willingness to give written informed consent

          -  Abstinence from alcohol for between 3 and 21 days

          -  Resolution of any clinically evident alcohol withdrawal (CIWA-AR)

        Exclusion Criteria:

          -  Active major psychological disorder associated with psychosis or significant suicide
             risk

          -  Pregnancy or lactation

          -  Concurrent use of any psychotropic medication other than antidepressants

          -  Substance use other than nicotine if unstable

          -  Clinical evidence of persisting hepatic encephalopathy

          -  Pending incarceration

          -  Lack of stable housing

          -  Active peptic ulcers

          -  Unstable diabetes mellitus
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul S Haber, MBBS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sydney Local Health District</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Andrew Baillie, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Macquarie University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kirsten Morley, PhD</last_name>
    <phone>+61295153636</phone>
    <email>kirsten.morley@sydney.edu.au</email>
  </overall_contact>
  <location>
    <facility>
      <name>Drug Health Services, Royal Prince Alfred Hospital</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2050</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kirsten C Morley, PhD</last_name>
      <phone>+61295153636</phone>
      <email>kirsten.morley@sydney.edu.au</email>
    </contact>
    <contact_backup>
      <last_name>Central Intake</last_name>
      <phone>95157611</phone>
      <email>sydneyalcoholtreatmentgroup@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Paul Haber, MBBS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>May 2013</verification_date>
  <lastchanged_date>May 8, 2013</lastchanged_date>
  <firstreceived_date>October 16, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>South West Sydney Local Health District</investigator_affiliation>
    <investigator_full_name>Professor Paul Haber</investigator_full_name>
    <investigator_title>Medical Director</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Liver Diseases, Alcoholic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Baclofen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
